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R
NA interference (RNAi) has 
been called “one of the most 
exciting discoveries in biology 
in the last couple decades,” and since it 
was ﬁ  rst recognized by Andrew Fire et 
al. in 1998, it has quickly become one 
of the most powerful and indispensable 
tools in the molecular biologist’s 
toolkit. Using short double-stranded 
RNA (dsRNA) molecules, RNAi 
can selectively silence essentially any 
gene in the genome. It is an ancient 
mechanism of gene regulation, found 
in eukaryotes as diverse as yeast and 
mammals, and probably plays a central 
role in controlling gene expression 
in all eukaryotes. In the lab, RNAi is 
routinely used to reveal the genetic 
secrets of development, intracellular 
signaling, cancer, infection, and a full 
range of other phenomena. But can 
the phenomenon hailed by the journal 
Science as the “Breakthrough of the Year” 
in 2002 break out of the lab and lead to 
novel therapies as well? Pharmaceutical 
giants are hoping so, and several biotech 
companies have bet their futures on it, 
but not everyone is sanguine about the 
future of RNAi therapy.
At the heart of its promise as a 
powerful therapeutic drug lies the 
exquisite selectivity of RNAi: like 
the fabled “magic bullet,” an RNAi 
sequence seeks out and destroys its 
target without affecting other genes. 
The clinical applications appear 
endless: any gene whose expression 
contributes to disease is a potential 
target, from viral genes to oncogenes 
to genes responsible for heart disease, 
Alzheimer’s disease, diabetes, and more. 
But for all its promise, RNAi therapy 
is a long way from entering the clinic. 
While it is a proven wunderkind in 
the lab, to date no tests have been 
done in humans, and only the most 
modest and circumscribed successes 
have been demonstrated in animals. 
The road to clinical success is littered 
with great ideas that have come a 
cropper along the way, including two 
other RNA-based therapies, antisense 
and ribozymes, both of which showed 
promise at the bench but have largely 
stumbled before reaching the bedside. 
Is RNAi also likely to fall short? Or is it 
different enough to make this third try 
the charm?
Clinical Naïveté, Mysterious 
Mechanisms
To be a successful drug, a 
molecule must overcome a long set 
of hurdles. First, it must be able to be 
manufactured at reasonable cost and 
administered safely and conveniently. 
Then, and even more importantly, 
it must be stable enough to reach its 
target cells before it is degraded or 
excreted; it must get into those cells, 
link up with its intracellular target, 
and exert its effect; and it must exert 
enough of an effect to improve the 
health of the person taking it. And, 
ﬁ  nally, it must do all this without 
causing signiﬁ  cant toxic effects in 
either target or nontarget tissues. No 
matter how good a compound looks 
in the lab, if it fails to clear any one of 
these hurdles, it is useless as a drug. 
For RNA-based therapies, 
manufacture has been seen as a soluble 
problem, while delivery, stability, 
and potency have been the most 
signiﬁ  cant obstacles. “There was a lot 
of clinical naïveté” in the early days of 
antisense and ribozymes, according 
to Nassim Usman, Vice President for 
Research and Development at Sirna 
Therapeutics in Boulder, Colorado. 
“Compounds were pushed into the 
clinic prematurely.” Sirna began 
as the biotech startup Ribozyme 
Pharmaceuticals, which tried to 
develop ribozymes to treat several 
conditions, including hepatitis C. A 
ribozyme is an RNA molecule whose 
sequence and structure allow it to 
cleave speciﬁ  c target RNA molecules 
(see Figure 1). “The initial results with 
hepatitis C were not that inspiring,” 
says Usman, because the molecule 
they used had low potency and a short 
half-life once in the body. Despite 
“enormous doses,” the viral load was 
not signiﬁ  cantly affected. “It just didn’t 
have the characteristics to be a drug,” 
he says. No ribozyme has yet been 
approved for use by the United States 
Food and Drug Administration (FDA).
Similarly, despite much initial 
enthusiasm, attempts to develop 
antisense drugs have been largely 
disappointing. Antisense is a single 
strand of RNA or DNA, complementary 
to a target messenger RNA (mRNA) 
sequence; by pairing up with it, the 
antisense strand prevents translation of 
the mRNA (see Figure 2). At least that 
was the theory, and early clinical results 
seemed to support the theory: antisense 
drugs effectively reduced tumor sizes 
in anticancer trials and viral loads in 
antiviral trials. But closer inspection 
revealed these results were largely 
due to an increase in production of 
interferons by the immune system in 
response to high doses of the foreign 
RNA, rather than to speciﬁ  c silencing 
of any target genes. (The relatively 
high proportion of C–G sequences in 
antisense mimics bacterial and viral 
genes, thus triggering the immune 
response.) When the antisense dose 
was lowered to prevent the interferon 
response, the clinical beneﬁ  t largely 
disappeared as well. Thus, rather 
than being a highly speciﬁ  c therapy, 
antisense seemed to be a general 
immune system booster. 
Feature
RNAi Therapeutics: How Likely, How Soon?
Richard Robinson
Copyright: © 2004 Richard Robinson. This is an 
open-access article distributed under the terms of 
the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is 
properly cited.
Abbreviations: dsRNA, double-stranded RNA; FDA, 
Food and Drug Administration; mRNA, messenger 
RNA; RISC, RNA-induced silencing complex; RNAi, RNA 
interference; siRNA, short interfering RNA
Richard Robinson is a freelance science writer from 
Sherborn, Massachusetts, United States of America. 
E-mail: rrobinson@nasw.org
DOI: 10.1371/journal.pbio.0020028
DOI: 10.1371/journal.pbio.0020028.g001
Figure 1. Ribozymes
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But as long as patients were getting 
better, does it matter what the 
mechanism was? “It doesn’t matter if 
you are a patient, but it does matter 
if you are trying to develop the next 
drug,” says Cy Stein, Associate Professor 
of Medicine and Pharmacology at 
Columbia University College of 
Physicians and Surgeons in New York 
City. Stein has researched antisense 
for more than a decade. “If you get the 
mechanism wrong, you’re not going to 
be able to do it.” 
To date, only one antisense 
drug has received FDA approval. 
Vitravene, from Isis Pharmaceuticals 
in Carlsbad, California, is used to 
treat cytomegalovirus infections in the 
eye for patients with HIV. Vitravene 
is actually a DNA antisense drug, 
which binds to viral DNA, though, 
says Usman, “it’s unclear whether 
it actually works by an antisense 
mechanism.” Stein expresses a similar 
skepticism about the mechanism of 
a second antisense drug, Genasense. 
Genasense is a DNA-based treatment 
that targets Bcl-2, a protein expressed 
in high levels in cancer cells, which is 
thought to protect them from standard 
chemotherapy. The FDA is currently 
reviewing an application for Genasense, 
based on promising results in the 
treatment of malignant melanoma. 
RNAi: A Natural Alternative
Growing disillusionment with 
antisense and ribozymes coincided 
with the discovery of RNAi and the 
realization that it was a far more potent 
way to silence gene expression. RNAi 
uses short dsRNA molecules whose 
sequence matches that of the gene 
of interest. Once in a cell, a dsRNA 
molecule is cleaved into segments 
approximately 22 nucleotides long, 
called short interfering RNAs (siRNAs) 
(see Figure 3). siRNAs become bound 
to the RNA-induced silencing complex 
(RISC), which then also binds any 
matching mRNA sequence. Once 
this occurs, the mRNA is degraded, 
effectively silencing the gene from 
which it came. (Details of the structure 
and function of the RISC are still 
largely unknown, but it is thought 
to act as a true enzyme complex, 
requiring only one or several siRNA 
molecules to degrade many times that 
number of matching mRNAs.)
The extraordinary selectivity of 
RNAi, combined with its potency—in 
theory, only a few dsRNAs are needed 
per cell—quickly made it the tool 
of choice for functional genomics 
(determining what a gene product 
does and with what other products it 
interacts) and for drug target discovery 
and validation. By “knocking down” a 
gene with RNAi and determining how 
a cell responds, a researcher can, in 
the course of only a few days, develop 
signiﬁ  cant insight into the function 
of the gene and determine whether 
reducing its expression is likely to be 
therapeutically useful. But does RNAi 
have a better chance to succeed as a 
drug than antisense or ribozymes?
“The fundamental difference 
favoring RNAi is that we’re harnessing 
an endogenous, natural pathway,” says 
Nagesh Mahanthappa, Director of 
Corporate Development at Alnylam 
Pharmaceuticals in Cambridge, 
Massachusetts, the second of two 
major biotech company developing 
RNAi-based therapy. The exploitation 
of a pre-existing mechanism, he says, 
is the main reason RNAi is orders of 
magnitude more potent than either of 
the other two types of RNA strategies.
Delivery, Delivery, Delivery
More potent in the test tube, at 
least. But stability and delivery are 
also the major obstacles to successful 
RNAi therapy, obstacles that are 
intrinsic to the biochemical nature 
of RNA itself, as well as the body’s 
defenses against infection with foreign 
nucleotides. “For the strongest reasons, 
you can’t get away from this,” says 
Stein. “The problem is that a charged 
oligonucleotide will not pass through a 
lipid layer,” which it must do in order 
to enter a cell. John Rossi, Director 
of the Department of Molecular 
Biology at City of Hope Hospital in 
Duarte, California, who has worked 
on RNA-based therapies for 15 years, 
concurs. “The cell doesn’t want to 
take up RNA,” he says, which makes 
evolutionary sense, since extracellular 
RNA usually signiﬁ  es a viral infection. 
Injected into the bloodstream, 
unmodiﬁ  ed RNA is rapidly excreted by 
the kidneys or degraded by enzymes. 
To solve the problem of cell 
penetration, most researchers have 
either complexed the RNA with a lipid 
or modiﬁ  ed the RNA’s phosphate 
backbone to minimize its charge. 
Mahanthappa thinks the complexing 
approach is unlikely to be a simple 
solution, since drug approval would 
require independent testing of the lipid 
delivery system as well. Instead, Alnylam 
is pursuing backbone modiﬁ  cation. 
“Some minimal modiﬁ  cation is going 
to be necessary” to increase cell uptake 
and to improve stability in the blood 
stream, Mahanthappa says. “What we 
have learned from the antisense ﬁ  eld 
is that even without other delivery 
strategies, when you administer RNA 
at sufﬁ  cient doses, if it’s stable, it gets 
taken up by cells.”
“Anything that can be done to 
increase half-life in circulation would 
improve delivery,” says Judy Lieberman, 
a Senior Investigator at the Center for 
Blood Research and Associate Professor 
of Pediatrics at Harvard Medical School 
in Cambridge, Massachusetts. But 
that may not be the only problem, she 
cautions. Lieberman’s lab recently 
DOI: 10.1371/journal.pbio.0020028.g002
Figure 2. Antisense
Antisense DNA or RNA binds to a speciﬁ  c mRNA and prevents it from being translated 
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demonstrated the ability of RNAi to 
silence expression of the Fas gene in 
mice, protecting them from fulminant 
hepatitis. Fas triggers apoptosis, or 
programmed cell death, in response 
to a variety of cell insults. In her 
experiment, Lieberman delivered 
the RNA by high-pressure injection 
into the tail. The RNA got to the 
liver, silenced Fas, and protected 
the mice from hepatitis. However, a 
signiﬁ  cant fraction of animals died of 
heart failure, brought on because the 
injection volume was about 20% of the 
mouse blood volume. Such a delivery 
scheme simply will not work in humans. 
“Delivery to the cell is still an obstacle,” 
Lieberman explains. “Unless you really 
focus on how to solve that problem, 
you’re not going to get very far.”
Unanswered Questions
Even assuming delivery problems 
can be solved, other questions remain, 
including that of whether therapeutic 
levels of RNAi may be toxic. 
Mahanthappa says, “The conservative 
answer is we just don’t know. The more 
aggressive answer is there’s no reason 
to think so.” Rossi isn’t so sure. “The 
target of interest may be in normal cells 
as well as cancer cells,” he says. “That’s 
where you get toxicity.” 
But if small RNAs can be delivered 
to target cells efﬁ  ciently and without 
signiﬁ  cant toxicity, will they be effective 
medicines? Usman of Sirna is conﬁ  dent 
they will be. “If you can get it there, 
and if it’s in one piece, there no doubt 
in our minds that it will work,” he 
says. To date, numerous experiments 
in animal models suggest RNAi can 
downregulate a variety of target genes 
effectively. However, there are still two 
unanswered questions about whether 
that will translate into effective therapy.
The ﬁ  rst is whether RNAi’s exquisite 
speciﬁ  city is really an advantage beyond 
the bench. “It’s unclear whether highly 
speciﬁ  c drugs give you a big therapeutic 
effect,” says Cy Stein. For instance, he 
says, “most active antitumor medicines 
have multiple mechanisms of action. 
The more speciﬁ  c you make it, the less 
robust the therapeutic activity is likely 
to be.” Rossi agrees: “Overspeciﬁ  city 
has never worked,” he says. 
The second question is what effect 
an excess of RNA from outside the 
cell will have on the normal function 
of the RISC, the complex at the heart 
of the RNAi mechanism. The number 
of RISCs in the cell is unknown, and 
one concern is that the amount of 
RNA needed to have a therapeutic 
effect may occupy all the available 
complexes. “We are usurping a natural 
cell system that is there for some other 
purpose, for knocking out endogenous 
gene function,” says Rossi. With the 
introduction of foreign RNA, will the 
system continue to perform its normal 
function as well, or will it become 
saturated? “That’s the big black box in 
the ﬁ  eld,” he says.
Looking Ahead to the Clinic
Despite the questions and unsolved 
problems, Sirna, Alnylam, and several 
other companies are moving ahead to 
develop RNAi therapy; indeed, some 
outstanding questions are probably 
only likely to be answered in the 
process of therapeutic development. 
The ﬁ  rst applications are likely to be 
in cancer (targeting out-of-control 
oncogenes) or viral infection (targeting 
viral genes). To avoid some of the 
problems of delivery, initial trials may 
deliver the RNA by direct injection 
into the target tissue (for a tumor, for 
instance) or ex vivo, treating white 
blood cells infected with HIV, for 
example.
Having spent a decade trying to 
develop ribozymes, says Usman, Sirna 
is prepared for the rough road it faces. 
“We haven’t solved all the problems, 
but we know how to proceed to work 
through them. It’s no surprise to us—
we’ve seen this movie before.” Usman 
expects Sirna to ﬁ  le an Investigational 
New Drug Application with the FDA 
by the end of 2004 and to have a 
human clinical trial in progress in 
2005. “Without a doubt, there will be 
an RNAi-based drug within ten years,” 
Usman predicts. 
Stein isn’t so sure and thinks that 
too much is still to be learned about 
RNAi and the body’s reaction to it to 
be conﬁ  dent that RNA-based therapies 
will ultimately be successful. “The 
whole ﬁ  eld was founded on the belief 
it was rational, but there are huge gaps 
in our knowledge, and so you need a 
bit of luck to be successful,” he says. 
“I think people are surprised at how 
complicated it is, but why should it 
be any other way? It’s an intellectual 
conceit to think that nature is simple.”  
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Figure 3. RNAi
RNAi is a recently described naturally occurring process in which small RNA molecules 
activate a cellular process that results in the destruction of a speciﬁ  c mRNA.